Back

Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion.

26 August 2023 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Arterial occlusive disease: a chronic pandemic needing attention to detail Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Sho Nakao

Kansai Rosai Hospital, Amagasaki (Japan)

8 More presentations in this session

Presentation thumbnail
Reduction in the risk of major adverse limb events with ezetimibe versus placebo in addition to statin therapy: insights from the IMPROVE IT trial
Doctor M. Bonaca (Aurora, US)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) and the risk of major adverse limb events in patients with stable atherosclerotic vascular disease
Doctor M. Bonaca (Aurora, US)
Abstract Slides Video
Presentation thumbnail
The impact of Covid-19 on mortality and clinical characteristics in hospitalized patients with peripheral artery disease in the year 2020
Professor C. Hehrlein (Freiburg, DE)
Abstract Slides Video
Presentation thumbnail
Association between electronic nicotine delivery systems use and risk of stroke: A systematic review and meta-analysis of observational studies with 822,162 participants.
Professor M. Banach (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Olive extract enriched with hydroxytyrosol improves cardiac and vascular function in patients with stable coronary artery disease: a double-blind, placebo-controlled trial.
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Arterial occlusive disease: a chronic pandemic needing attention to detail

The Event

Event poster

ESC Congress 2023

26 August 2023 11:15 CET
You may be interested in
thumbnail
Congress Session
Cardiovascular treatment: protecting the brain and the limbs
thumbnail
Congress Session
Late-breaking science on acute coronary syndromes
thumbnail
Congress Session
Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources